Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

, AXN, BLD, RIC, PWRM - Stock Update From!




Power3 Medical Products, Inc. (OTC.BB:PWRM) business focus is the development of commercial applications for their proprietary technologies. The scientific team is on the leading edge of the proteomics industry through their discovery of protein footprints, pathways, and mechanisms of disease. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer, neurodegenerative disease and drug resistance in cancer. The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.

Alzheimer's disease just isn't an everyday aspect of increasing age, although the most significant identified risk factor is increasing age, and most individuals with Alzheimer's are 65 and older. Alzheimer's is just not a illness connected with senior years. As much as five percent of people with the actual condition have early-onset Alzheimer's (also called younger-onset), which frequently appears when someone is in an individual's 40s or 50s.

Soon after cancer of the skin, cancer of the breast is easily the most well-known cancer diagnosis in females in the USA. However, breast cancer rates currently have gone down these days, though doctors aren't certain why. Even now, for many females, breast cancer may be the health probem that they fear most.

Parkinson's disease is really a problem that affects nerve cells, or neurons, inside of a section of the brain of which controls muscle motions. In Parkinson's, nerves which make an important chemical called dopamine die or do not work properly. Dopamine generally delivers impulses that assist synchronize a person's activities.


Richmont Mines Inc. (AMEX:RIC) is pleased to announce additional drilling results from the Wasamac property that provide further support for the Company’s plan to reassess the property’s resource base using a lower cut-off grade. President and CEO Martin Rivard commented: “We are very enthusiastic about Wasamac’s long-term potential for Richmont and our shareholders. Overall drilling results support our plan to reassess the property’s resource base using a lower-cut off grade to expand the mineralized envelope.

Richmont Mines has produced over 1,000,000 ounces of gold from its operations in Quebec, Ontario and Newfoundland since beginning production in 1991.


Baldwin Technology Co. Inc. (AMEX:BLD) a leader in process automation technology for the global printing industry, announced that its US graphics operations received orders in November of more than $4 million. The November orders bring the year-to-date orders for the Baldwin Americas operation to a 23% increase over orders recorded in the same period in 2009. The November activity includes equipment orders of more than $1 million from Quad/Graphics, a major U.S. commercial printer. Baldwin’s new cloth and brush automatic blanket cleaners and new spray dampening technology, together with water systems from our alliance partner, AWS, will significantly enhance the productivity of several of Quad/Graphics new and existing presses while simultaneously improving the quality of the printed product.

Baldwin Technology Company, Inc. is a leading international supplier of process automation equipment and related consumables for the printing and publishing industries.


Aoxing Pharmaceutical Company, Inc. (AMEX:AXN) a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced initiation of the registration clinical trial of Buprenorphine/Naloxone sublingual tablets, indicated for opioid addiction treatment. The registration trial, approved by the SFDA, will be administered by the National Institute of Drug Dependence in China at Beijing University, the co-development partner for Aoxing Pharma.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products.




Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).